Oct 2026· Hematology/Oncology Clinics of North America· Vol 40 5, pp.
685-704
· 0 citations· 91 references
Medicine
TL;DR
Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy, and the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB.
Abstract
With multiple molecular targeted therapies available for patients with cancer that correspond to a specific genetic alteration, the selection of the best treatment is essential to ensure therapeutic efficacy. Molecular tumor boards (MTBs) play a key role in this process to deliver personalized medicine to patients with cancer in a multidisciplinary manner. Historically, personalized medicine has been offered to patients with advanced cancer, but the incorporation of molecular targeted therapies and immunotherapy into the perioperative setting requires clinicians to understand the role of the MTB. Evidence is accumulating to support feasibility and survival benefit in patients treated with matched therapy.
Pediatric precision oncology has provided a greater understanding of the wide range of molecular alterations in difficult-to-treat or rare tumors with the aims of increasing survival as well as decreasing toxicity and morbidity from current cytotoxic therapies. In this article, the authors discuss the current state of...
William G. Lee, Eugene S. Kim· Hematology/Oncology Clinics...· 0 citations
Cancer therapeutics has been revolutionized by the introduction of molecularly targeted therapies and immune checkpoint inhibitors (ICIs). The paradigm of neoadjuvant therapy is commonly employed across multiple solid tumors, exhibiting significant clinical benefit as exemplified with ICIs in melanoma and non-small-cel...
D. Nishizaki, R. N. Eskander· Hematology/Oncology Clinics...· 0 citations
Outcomes for patients with breast cancer have improved over time due to increased screening and the availability of more effective therapies. It is important to recognize that breast cancer is a heterogeneous disease that requires treatment based on molecular characteristics. Early endpoints such as pathologic complete...
A. Abbasi, Vincent Wu, J. Lang et al.· Hematology/Oncology Clinics...· 0 citations
Overall, targeted cancer therapy gradually strengthens personalized cancer management and remains an important area for future oncology research and clinical practice.
Nataraj Palaniyappan, Vijayakumar Murugesan, Kannan Arumugam et al.· International journal of med...· 0 citations
Simple Summary Cancer treatment guidelines are based on results from groups of patients and remain the foundation of cancer care. However, some patients, especially those with rare cancers or cancers that no longer respond to standard treatments, reach a point where guidelines provide no further treatment option. This...
J. Lisziewicz, Oliver Wueseke, F. Lori· Cancers· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
